Related references
Note: Only part of the references are listed.Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody
Srinath Kasturirangan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
The making of bispecific antibodies
Ulrich Brinkmann et al.
MABS (2017)
ABiparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y. Li et al.
CANCER CELL (2016)
PyIgClassify: a database of antibody CDR structural classifications
Jared Adolf-Bryfogle et al.
NUCLEIC ACIDS RESEARCH (2015)
Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer
Takayasu Kurata et al.
INVESTIGATIONAL NEW DRUGS (2014)
Design and characterization of structured protein linkers with differing flexibilities
Joshua S. Klein et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2014)
Dual HER2 blockade: preclinical and clinical data
Tejal A. Patel et al.
BREAST CANCER RESEARCH (2014)
Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival
Joseph J. Maly et al.
BREAST CANCER-BASIC AND CLINICAL RESEARCH (2014)
Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family
Anton Arkhipov et al.
ELIFE (2013)
A single ligand is sufficient to activate EGFR dimers
Ping Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
REFMAC5 for the refinement of macromolecular crystal structures
Garib N. Murshudov et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
Overview of the CCP4 suite and current developments
Martyn D. Winn et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
A New Clustering of Antibody CDR Loop Conformations
Benjamin North et al.
JOURNAL OF MOLECULAR BIOLOGY (2011)
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
Jeffrey L. Nordstrom et al.
BREAST CANCER RESEARCH (2011)
Structural Evidence for Loose Linkage between Ligand Binding and Kinase Activation in the Epidermal Growth Factor Receptor
Chafen Lu et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
Spatial control of EGF receptor activation by reversible dimerization on living cells
Inhee Chung et al.
NATURE (2010)
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Neil L. Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The Design and Characterization of Oligospecific Antibodies for Simultaneous Targeting of Multiple Disease Mediators
Nazzareno Dimasi et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Jenny Bostrom et al.
SCIENCE (2009)
Quantitative understanding of the energy transfer between fluorescent proteins connected via flexible peptide linkers
Toon H. Evers et al.
BIOCHEMISTRY (2006)
Studying multiprotein complexes by multisignal sedimentation velocity analytical ultracentrifugation
A Balbo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains
H Ogiso et al.
CELL (2002)
HER2/Neu: mechanisms of dimerization/oligomerization
PJ Brennan et al.
ONCOGENE (2000)
The ErbB signaling network: receptor heterodimerization in development and cancer
MA Olayioye et al.
EMBO JOURNAL (2000)
Evolutionary analysis of the ErbB receptor and ligand families
RA Stein et al.
JOURNAL OF MOLECULAR EVOLUTION (2000)
Share Paper
